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Abstract
Invasive fungal infections (IFIs) represent important complications in patients with haematological malignancies. Chemoprevention of IFIs
may play an important role in this setting, but in the past decades the majority of antifungal drugs utilized demonstrated poor efﬁcacy,
particularly in the prevention of invasive aspergillosis. The new triazoles are very useful antifungal drugs, more suitable for prophylaxis of IFIs
than amphotericin B and echinocandins. In this review, the main clinical data about antifungal prophylaxis with ﬂuconazole, itraconazole,
voriconazole and posaconazole are analysed. At present, posaconazole appears to be the most efﬁcacious azole in antifungal prophylaxis,
particularly in patients with acute myeloid leukaemia.
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Epidemiology of Fungal Infections in
Haematology
Invasive fungal infections (IFIs) are a leading infectious cause of
morbidity and mortality in patients with haematological
malignancies [1]. Patients with haematological malignancies
such as acute leukaemia, myelodysplastic syndromes and those
undergoing allogenic haemopoietic stem cell transplant
(allo-HSCT) are at major risk of IFIs [2]. In particular, the
incidence of IFIs is higher in acute myeloid leukaemia (AML)
[3]. In the recent past, some studies evaluated the incidence
and outcome of IFIs in haematological malignancies. A retro-
spective study, conducted in a population of 11 802 haema-
tological malignancies treated with conventional
chemotherapy, showed an overall incidence of 4.6% proven/
probable IFIs, but the incidence of IFIs was highest among
patients with AML (c. 8%). In some settings, IFIs caused by
moulds are more frequent than those caused by yeasts, and
Aspergillus spp is the most common pathogen [4]. The risk of
invasive aspergillosis (IA) is not constant over all the phases of
AML treatment: the majority of AML patients usually experi-
ence IA after the ﬁrst cycle of chemotherapy (1st induction),
the ﬁrst time that a colonized patient experiences deep
immunosuppression. An IFI during the ﬁrst induction may
dramatically compromise the following therapeutical strategy
for AML [5].
For this reason, antifungal prophylaxis of IFIs may have an
important role in this setting; in the past decades, chemopro-
phylaxis with oral polyenes and old triazoles showed poor
efﬁcacy. At present, the availability of new triazoles (i.e.
voriconazole, posaconazole) characterized by a wider spec-
trum may have modiﬁed the role of antifungal prophylaxis. In
this review, the efﬁcacy of the different antifungal prophylaxis
used over the years will be analysed.
Past Role of Chemoprophylaxis
Several review articles evaluated the role of the prophylaxis of
IFIs in the pre-new antifungals era [6–10]. Topical therapy with
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oral polyenes has the potential to prevent candidiasis with less
risk of side effects and drug interactions than systemic therapy.
It has been found useful in prevention of serious Candida
infection in high-risk patients [9,10]. However, this kind of
prophylaxis has been disappointing, particularly against Asper-
gillus.
Some years ago, Uzun and Anaissie described some criteria
to identify the optimal antifungal agent. The ideal prophylactic
agent should be safely administrable over long periods,
effective, fungicidal against a wide spectrum of fungal patho-
gens, inexpensive, available in both oral and intravenous
formulation and associated with a low incidence of resistance
[11]. These criteria identiﬁed triazoles as a very useful class of
oral antifungal drugs, more suitable for chemoprophylaxis of
IFIs than AmB and other drugs, available only in intravenous
(iv) formulation.
Fluconazole
Fluconazole was the ﬁrst azole systematically used for
chemoprophylaxis of IFIs. Due to its high systemic activity
and low toxicity, ﬂuconazole facilitated an earlier and prophy-
lactic use of systemic antifungals, and it is not contraindicated
in patients receiving cyclosporine prophylaxis against graft-ver-
sus-host disease (GVHD). However, it appears effective only in
high doses, commonly associated with adverse reactions [6–8].
Fluconazole is active against the most of Candida strains,
although some strains are inherently resistant (i.e. Candida
kruzei or Candida glabrata) [12].
Randomized, double-blind, placebo-controlled trials evalu-
ated ﬂuconazole as antifungal prophylaxis for HSCT recipients.
Goodman et al. studied 356 autologous and allo-HSCT recip-
ients from multiple centres, using ﬂuconazole (400 mg/day) or
placebo from the start of the conditioning period for a
maximum of 10 weeks. IFIs occurred in 28 patients who
received placebo as compared with ﬁve who received
ﬂuconazole (15.8% vs. 2.8%, p < 0.001). Fluconazole pre-
vented infection with all species of Candida except C. krusei.
Fewer infection-related deaths occurred in the ﬂuconazole
arm of the study (1/179 vs. 10/177, p < 0.001), but ﬂuconazole
did not signiﬁcantly alter overall mortality [13]. In a second
study, Slavin and coworkers sought to determine whether a
longer course of prophylaxis with ﬂuconazole would improve
survival or lower the incidence of infections. They adminis-
tered ﬂuconazole (400 mg/day for 75 days) to allo-HSCTs.
The rate of IFIs in the ﬂuconazole arm during prophylaxis was
10/152 patients (7%) vs. 26/148 patients (18%) in the placebo
arm (p 0.004). The rate of IFI-related deaths by day 110 after
transplant was 13% in the ﬂuconazole arm and 21% in the
placebo arm (p 0.005). In contrast to the Goodman study, at
day 110, the probability of overall survival was improved
among ﬂuconazole recipients (20% vs. 35%, p = 0.004) [14].
However, it is noteworthy that at time of these studies,
Candida spp. caused the majority of IFI, and this may explain
ﬂuconazole’s good performance.
A post-mortem study carried out on 720 patients given
ﬂuconazole prophylaxis showed that they died of Candida
infection less frequently than of Aspergillus IFI; however, it must
be taken in account that the sensitivity of blood cultures
decreased when patients received ﬂuconazole prophylaxis, a
possible evaluation bias. [15]. Several authors demonstrated
that the intensive use of ﬂuconazole prophylaxis in haemato-
logical malignancies selected multiresistant and difﬁ-
cult-to-treat species of Candida non-albicans [4,16–19].
Recent nationwide data in Denmark reported an increasing
incidence of candidemia associated with a decreasing propor-
tion being susceptible to ﬂuconazole. The ﬂuconazole MICs for
C. glabrata and C. krusei were in general elevated compared
with those for C. albicans; for C. glabrata in particular, the MIC
distribution suggests acquired resistance mechanisms for a
proportion of isolates [20].
Itraconazole
In contrast to ﬂuconazole, itraconazole is active against
Aspergillus spp; two studies compared the prophylactic activity
of these two drugs in haematological patients undergoing
allo-HSCT. In the ﬁrst study, itraconazole in oral solution
form was administered, and a signiﬁcant reduction in IFIs
incidence with itraconazole without differences in fungal-free
survival was observed [21]. In a second study, itraconazole
was administered initially intravenously and then as oral
solution, and resulted in fewer proven IFIs and lower
fungal-related mortality, but similar overall mortality, com-
pared to ﬂuconazole after allo-HSCT [22]. In both studies,
mild gastrointestinal side effects in itraconazole arm were
observed.
The study of the GIMEMA-infection group (Gruppo
Italiano Malattie Ematologiche dell’Adulto) that compared
itraconazole oral solution to placebo, did not show advantage
to itraconazole regarding the incidence of invasive aspergil-
losis, but a signiﬁcant reduction in candidemia was observed
[23].
However, an interesting meta-analysis evaluated the efﬁcacy
of itraconazole vs. other forms of prophylaxis for the
prevention of IFIs in neutropenic cancer patients after
chemotherapy or allo-HSCT. The meta-analysis of 13 ran-
domized trials in 3597 neutropenic patients with haematolog-
ical malignancies showed a signiﬁcant reduction in the
incidence of IFIs (p 0.002), of invasive yeast infections
(p 0.004) and mortality from IFIs (p 0.04), with a highly
signiﬁcant dose–response relationship [24].
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The use of itraconazole as prophylaxis is limited by the poor
drug absorption, when given in capsules, and by the gastro-
intestinal side effects, when given as oral suspension [21,22].
The New Triazoles
Voriconazole
Voriconazole is available for clinical use since 2003 and was
initially used for the targeted treatment of Aspergillus spp.
infections. Some recent clinical trials tried to demonstrate its
efﬁcacy also as antifungal prophylaxis. A multicenter, random-
ized, double-blind trial compared ﬂuconazole (N = 295) vs.
voriconazole (N = 305) for 100 days (180 days in higher-risk
cases) for the prevention of IFIs in patients undergoing
myeloablative allo-HSCT. Despite a nonsigniﬁcant trend for
fewer Aspergillus infections in favour of voriconazole (9 vs. 17,
p-value 0.05), the authors reported no signiﬁcant differences in
IFI incidence (7.3% vs. 11.2%), and empiric antifungal therapy
use (24.1% vs. 30.2%), while fungal-free survival rates (75% vs.
78%) at 180 days and overall survival were similar between
ﬂuconazole and voriconazole [25]. The prospective, random-
ized, open-label, multicentre study by Marks et al. compared
the efﬁcacy and safety of voriconazole (234 patients) vs.
itraconazole oral solution (255 patients) in allo-HSCT recip-
ients. The efﬁcacy of prophylaxis was signiﬁcantly higher with
voriconazole than itraconazole (48.7% vs. 33.2%, p < 0.01);
itraconazole patients received more often other systemic
antifungals (41.9% vs. 29.9%, p < 0.01) but more patients
tolerated voriconazole prophylaxis for 100 days (53.6% vs.
39.0%, p < 0.01). However, no difference in terms of incidence
of proven/probable IFIs (1.3% vs. 2.1%) or survival to day 180
(81.9% vs. 80.9%) was observed for voriconazole and itraco-
nazole, respectively [26].
These studies failed to show signiﬁcant beneﬁt for vorico-
nazole compared with itraconazole or ﬂuconazole in antifungal
prophylaxis.
Posaconazole
Posaconazole, available for clinical use since 2007, is a
new-generation oral azole with in vitro activity against a wide
spectrum of medically important fungi, including Candida spp.,
Aspergillus spp., Zygomycetes and Fusarium [27]. In vitro suscep-
tibility may vary among Zygomycetes and Fusarium species, and
there are no in vivo data on the efﬁcacy against these rare fungi
[28–30].
A randomized, multicenter single-blind study conducted by
Cornely et al., evaluated the efﬁcacy and safety of posaco-
nazole (n = 304) compared to ﬂuconazole (n = 240) or
itraconazole (n = 58) as prophylaxis for each cycle of
chemotherapy (until recovery from neutropenia and com-
plete remission or for up to 12 weeks) in patients with AML
or myelodysplastic syndrome and prolonged neutropenia.
The primary endpoint was the incidence of proven/probable
IFIs during treatment, and the secondary endpoints were
death from any cause and time to death. As far as the
primary endpoint is concerned, proven/probable IFIs were
observed in seven patients (2%) in the posaconazole group
and 25 patients (8%) in the pooled standard triazoles group
(absolute reduction in the posaconazole group, -6%; 95%
conﬁdence interval, 9.7 to 2.5%; p < 0.001) during the
on-treatment period (from randomization to 7 days after the
last dose of study drug). Signiﬁcantly fewer patients in the
posaconazole group had invasive aspergillosis (2 [1%] vs. 20
[7%], p < 0.001). Posaconazole maintained superiority over
pooled standard triazoles in preventing IFIs during the
100-day period after randomization: 14/304 (5%) vs. 33/298
(11%), p 0.003. Posaconazole was also signiﬁcantly better
than pooled standard triazoles in preventing IA during the
treatment phase (2 [1%] vs. 20 [7%], p < 0.001) and during
the 100-day period after randomization or ﬁxed time period
(4 [1%] vs. 26 [9%], p < 0.001). Survival was signiﬁcantly
longer among recipients of posaconazole than among recip-
ients of ﬂuconazole or itraconazole (p 0.04). Serious adverse
events possibly or probably related to treatment were
reported by 19 patients (6%) in the posaconazole group
and six patients (2%) in the ﬂuconazole or itraconazole group
(p 0.01) [27].
In another randomized double-blind trial, Ullmann et al.
compared oral posaconazole with oral ﬂuconazole for pro-
phylaxis against IFIs in 600 allo-HSCT recipients with GVHD
treated with immunosuppressive therapy. At the end of the
ﬁxed treatment (day 112), the difference in incidence of all
proven/probable IFIs between posaconazole and ﬂuconazole
arms was not signiﬁcant (5.3% and 9.0%, respectively; p 0.07),
but posaconazole was superior to ﬂuconazole in preventing
proven/probable IA (2.3% vs. 7.0%; p 0.006). During the
exposure period (time from ﬁrst dose to 7 days after the last
dose), posaconazole signiﬁcantly reduced the incidence of
breakthrough proven/probable IFIs (2.4% vs. 7.6%, p 0.004)
and IA (1.0% vs. 5.9%, p 0.001) vs. ﬂuconazole. Overall
mortality was similar in the two groups, but the number of
deaths from invasive fungal infections was lower in the
posaconazole group (1%, vs. 4% in the ﬂuconazole group;
p 0.046). The incidence of treatment-related adverse events
was similar in the two groups, such as the rates of
treatment-related serious adverse events (13% and 10%,
respectively) [31].
Posaconazole demonstrated to be clinically superior to
other triazoles in preventing IFIs (especially aspergillosis)
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among immunocompromised hosts. Furthermore, some
economical models reported posaconazole prophylaxis to be
a cost-effective strategy compared to old triazoles in high-risk
patients [32–34].
At present, posaconazole is only available in oral formu-
lation, and this has been associated with high interpatient (up
to 68% in adult patients) and intrapatient variability of drug
bioavailability [35,36]. Monitoring of drug plasma levels
should be performed whenever possible, in particular in
patients with impaired gastrointestinal absorption (due to
diarrhoea, mucositis, poor oral intake, vomiting) or in
patients receiving drugs known to either impair absorption
or increase clearance (i.e. proton pump inhibitors) [37].
Intravenous Prophylaxis
Deoxycolate AmB is not indicated as prophylaxis, due to its
relevant nephrotoxicity and poor efﬁcacy [38].
Caspofungin was the ﬁrst antifungal echinocandin to be
used for prophylaxis in patients with haematological malig-
nancies. The efﬁcacy and safety of caspofungin were similar
to other prophylactic regimens, and no great advantage in
its use was demonstrated [39,40]. In the study by Mattiuzzi
et al. [39] on 200 patients with haematological malignancies,
intravenous itraconazole and caspofungin provided similar
protection against IFIs during induction chemotherapy, and
both drugs were well tolerated. Similarly, the PROFIL-
C study comparing caspofungin to standard prophylaxis
(mainly itraconazole) did not show any advantage in terms
of IFI incidence, IA incidence, IFI-related mortality and safety
[40]. On the contrary, the analysis of data from a
multinational case registry by Vehreschild et al. [41] showed
a possible role of caspofungin as secondary antifungal
prophylaxis.
A prospective, randomized, double-blind comparative trial
study showed that micafungin compared with ﬂuconazole
seems to be a valid therapeutical option for prophylaxis
particularly in patients undergoing autologous or allo-HSCT.
The overall efﬁcacy of micafungin was superior to that of
ﬂuconazole during the neutropenic phase after HSCT [42]. In
another prospective study that compared micafungin with
itraconazole oral solution, non-inferiority of micafungin
regarding IFIs was observed [43]. Similar results were
observed in a prospective study where micafungin was
compared with a historical control of patients treated with
ﬂuconazole [44].
Some studies demonstrated the feasibility and safety of a
single weekly very high dose of liposomal AmB as antifungal
prophylaxis both in adult patients with acute myeloid leukae-
mia patients undergoing induction chemotherapy and immu-
nocompromised children [45,46]. Results of these studies are
interesting but based on very small series.
Meta-analysis and Guidelines
A meta-analysis published by Robenshtok et al. in 2007
evaluated the effect of antifungal prophylaxis on all-cause
mortality as primary outcome, IFIs, and adverse events in 64
randomized, controlled trials comparing systemic antifungals
with placebo, no intervention, no systemic antifungal prophy-
laxis in cancer patients after chemotherapy.
At the end of follow-up, antifungal prophylaxis signiﬁcantly
decreased all-cause mortality (RR 0.84; 95% CI 0.74–0.95). In
particular, in allo-HSCT recipients, prophylaxis reduced
all-cause mortality (RR 0.62; 95% CI 0.45–0.85), IFI-related
mortality (RR 0.52; 95% CI 0.27–0.74) and documented IFIs
(RR 0.50; 95% CI 0.41–0.99). In acute leukaemia patients, there
was a signiﬁcant reduction in documented IFIs (RR 0.69; 95%
CI 0.53–0.90), whereas the difference in mortality (RR 0.88;
95% CI 0.74–1.06) and IFIs-related mortality (RR 0.66; 95%
CI 0.44–1.00) was only borderline signiﬁcant. In particular,
prophylaxis with itraconazole suspension reduced docu-
mented IFI when compared to ﬂuconazole, with no difference
in survival but with more adverse events [47].
A more recent meta-analysis analysed 20 trials comparing
systemic mould-active vs. ﬂuconazole prophylaxis in cancer
patients receiving chemotherapy or allo-HSCT. Study regimens
included amphotericin B formulations (n = 4), micafungin
(n = 3), posaconazole (n = 2), voriconazole (n = 1) and itrac-
onazole (n = 10). The analysis conﬁrmed that mould-active
prophylaxis is preferable, due to a signiﬁcant reduction in the
number of proven/probable IFI (RR 0.71; 95% CI 0.52–0.98;
p 0.03), of invasive aspergillosis (RR 0.53; 95% CI 0.37–0.75;
p 0.0004) and IFI-related mortality (RR 0.67; 95% CI 0.47–0.96;
p 0.03) [48].
Based on these data, most of the clinical guidelines on
antifungal prophylaxis in AML and allo-HSCT recommend
posaconazole as antimould prophylaxis in immunocompro-
mised patients, especially after chemotherapy (Table 1) [49–
54]. IDSA guidelines recommend prophylaxis against Can-
dida spp in high-risk patients (acute leukaemia and
allo-HSCT) (evidence A-1) and consider ﬂuconazole, itrac-
onazole, voriconazole, posaconazole, micafungin and caspo-
fungin all acceptable alternatives. Posaconazole is
recommended as prophylaxis against Aspergillus spp in those
patients who are undergoing intensive chemotherapy for
acute myeloid leukaemia or myelodysplastic syndrome
(evidence B-1) [51].
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From Bench to Bedside
The main limitation of randomized controlled trials is that they
usually enrol ‘healthy’ patients and thus results cannot be
conﬁrmed in a real-life setting of unselected patients. For this
reason, real-life studies may be of help in assessing whether
results from randomized clinical trials can be translated into
clinical practice.
In the last few years, some real-life experiences conﬁrmed
the efﬁcacy of posaconazole prophylaxis in this clinical setting,
even if they were almost all retrospective studies and with
historical comparisons (Table 2) [33,57–64].
The recent prospective registry by SEIFEM (Sorveglianza
Epidemiologica Infezioni Fungine nelle Emopatie Maligne)
analysed the efﬁcacy of antifungal prophylaxis with posaconaz-
ole (n = 260) and itraconazole (n = 93) in a large series of
consecutive patients with AML during the ﬁrst induction of
remission. The results of this real-life study conﬁrmed those by
Cornely’s trial: there were signiﬁcant differences in favour of
posaconazole vs. itraconazole in terms of breakthrough
IFIs rate (18.9% vs. 38.7%, p < 0.001), proven/probable mould
infections rate (2.7% vs. 10.7%, p 0.02), mould-attributable
(0 vs. 4.3%, p 0.005) and overall mortality rate (3.5% vs. 9.7%
p 0.02) [61].
De Pauw et al. highlighted the ability of posaconazole to
suppress serum galactomannan (GM) expression, the more
useful parameter for identifying an IA [65,66], According to
several studies, sensitivity and diagnostic utility of GM may be
compromised during receipt of prophylactic or empirical
antifungal therapies [67–71]. This may explain why the SEIFEM
study showed a higher use of empirical than pre-emptive
therapy, after posaconazole prophylaxis [61].
Plasma therapeutic levels of posaconazole were not eval-
uated in the randomized clinical trials nor in the SEIFEM study
[50,61]; however, an in vitro study demonstrated that rapid
drug clearance makes difﬁcult a correct kinetic evaluation and
TABLE 1. Therapeutical recommendation by International
Guidelines on antifungal prophylaxis in AML and allo-HSCT
[47–49]
FLUCO VORICO ITRA POSA CASPO L-AmB MICA
ECIL-3–4 [49]
CT C-I – C-I A-I – C-I –
Allo-HSCT A-I A-I B-I A-I – C-I C-I
DGHO [50]
Neutropenic C-I CII C-I A-I C-I C-II –
Allo-HSCT A-I CII C-I A-I – – C-I
IDSA [51]
(against Candida)
AL A-I – A-I A-I A-I – A-I
Allo-HSCT A-1 – – A-1 – – A-I
IDSA [51]
(against Aspergillus)
AML-MDS – – – B-1 – – –
British
guidelines [52]
– – B-II A-I – B-II –
NCCN [53]
AML-MDS 2B 2B – 1 – 2B –
Allo-HSCT 1 2B 2B 2B – 2B 1
ESCMID [54]
Neutropenic
allo-HSCT
A-I A-I B-I A-II C-II B-II/C-III A-I/C-I
AML, acute myeloid leukaemia; allo-HSCT, allogenic haematopoietic stem cell
transplant; MDS, myelodysplastic syndrome; FLUCO, ﬂuconazolo; VORICO,
voriconazole; ITRA, itraconazole; POSA, posaconazole; CASPO, caspofungin;
L-AmB, liposomal Amphotericin B; MICA, micafungin, CT, chemotherapy; ECIL,
European Conference on Infections in Leukaemia; DGHO, German Society for
Haematology and Oncology; IDSA, Infectious Diseases Society of America;
NCCN, National Comprehensive Cancer Network; ESCMID, European Society of
Clinical Microbiology and Infectious Diseases.
TABLE 2. Incidence of proven/probable (according to current EORTC/MSG diagnostic criteria) invasive fungal infections in acute
myeloid leukaemia after posaconazole prophylaxis: data from comparative studies [adapted from 33,56–64]
Posaconazole Comparator
N° pts Prov/prob IFIs (%) Prov/prob IA (%) DRUGS N° pts
Prov/prob
IFIs (%) p-value
Prov/prob
IA (%) p-value
AML
Michallet et al. [56] 55 — 2 (3.6) None 66 — nr 4 (6.1) nr
Hahn et al. [57] 21a 1 (4.7) — ﬂuco 21a 1 (4.7) nr — nr
Egerer et al. [58] 76 1 (1.3) 1 (1.3) nr — — —
Vehreschild et al. [59] 77 3 (3.9) 2 (2.6) Topical polyenes 82 16 (19.5) 0.003 11 (13.4) 0.018
Ananda-Rajah et al. [60] 67 0 0 Fluco
Itra
vorico
36
49
58
6 (17)
4 (8.2)
1 (1.7)
nr 5 (13.9)
3 (6.1)
0
Girmenia et al. [63] 99 23 (23.2) 15 (15.1) Topical polyenes 58 30 (51.7) 0.0004 25 (43.1) 0.0002
Pagano et al. [61] 260 10 (3.8) 7 (2.7) Itra 93 13 (14) <0.001 9 (9.7) 0.02
Peterson et al. [64] 100 4 (4) — none 100 14 (14) nr —
Allo-HSCT
Sanchez-Ortega et al. [33]
(days 0-100)
33 0 — Itra 16 2 (12.5) 0.04 nr nr
Chaftari et al.b [62] 21 0 — wABLC 19 1 (5) 0.48 nr nr
Hahn et al. [57]
(Graft-vs-host disease)
15 1 (7) — ﬂuco 8 2 (25) nr nr nr
AML, acute myeloid leukaemia; wABCL, weekly lipid complex-Amphotericin B; nr, not reported; IFIs, invasive fungal infections; IA, invasive aspergillosis, allo-HSCT, allogenic
haematopoietic stem cell transplant.
aData on AML in ﬁrst induction only.
bEarly stop after interim analysis for safety reasons.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 6), 19–26
CMI Pagano and Caira Antifungal prophylaxis in haematological patients 23
that the concentration of posaconazole in mammalian host cell
membranes may represent a new mechanism to mediate drug
efﬁcacy. This may help in reinterpreting discrepancies between
serum antifungal levels and efﬁcacy [72].
Conclusion
Nowadays, antifungal prophylaxis in high-risk patients plays a
relevant role, and thanks to the availability of newer drugs,
better results are being reported in recent studies, both in
randomized clinical trials and in ‘real-life’ studies. According
to these data, posaconazole is now considered a promising
option, particularly in AML patients. The role of diagnostic
tools (i.e. GM, PCR) after posaconazole remains to be
deﬁned, as well as the optimal management of febrile
neutropenia in those patients that received this kind of
prophylaxis.
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